SEC62 and neoplasm: Furthermore, the latter work characterized a clinically tested small molecule and Calmodulin-antagonist (trifluoperazine/TFP) as being able to suppress the effects of SEC62 overexpression on ER stress tolerance and migratory potential of tumor cells.